Clover Biopharmaceuticals, Inc.
B-A10 Room No.1, Mansion
Chengdu Hi-tech Zone Hi-tech Incubation Park
Tianhe Incubator, Nan Yan Xian Tian Fu Avenue
About Clover Biopharmaceuticals, Inc.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
Founders: Peng Liang, Xiaodong Wang and Jianwei Zhu
CSO: Joshua Liang
COO: Zheng Ping
CIO: Pu Jiang
25 articles with Clover Biopharmaceuticals, Inc.
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.
Cytiva provides FlexFactory™ bioprocessing upstream and downstream solutions for Clover to accelerate GMP facility development and shorten time to market
10/2/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Clover Biopharmaceuticals Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program
Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific Advisory Board (SAB) comprised of internationally-renowned experts in the vaccine industry, public health and policy making
Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) EMERYVILLE, Calif. and CHENGDU, China, March 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Clover Biopharmaceut
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate.
Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients
Clover Biopharmaceuticals announced that it has successfully produced its trimeric Spike-protein subunit vaccine candidate for 2019-nCoV via a mammalian cell expression system.
Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Wuhan Coronavirus (2019-nCoV)
Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has initiated development of a recombinant subunit vaccine for 2019-nCoV, the newly identified coronavirus that is believed to have originated from Wuhan, China.
Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.
Clover Biopharmaceuticals Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in China
The Phase III, multi-center trial in China is designed to assess the efficacy, safety and pharmacokinetics of SCB-808 and originator drug Enbrel® in patients with ankylosing spondylitis (radiographic axial spondyloarthritis) via subcutaneous administration.
Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced the completion of a US$ 43 million Series B financing.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
Clover Biopharmaceuticals announced that the first patient was dosed in a Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in Australia for the treatment of cancer patients with malignant pleural effusions.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites
Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the treatment of cancer patients with malignant ascites.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal Carcinomatosis
The Phase I, open-label, dose escalation trial in China is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of intraperitoneally administered SCB-313 as a single-agent for the treatment of peritoneal carcinomatosis.
Clover Health Launches Clover Therapeutics, a New Research Subsidiary to Develop Treatment for Chronic Diseases
Newly inked research collaboration and license agreement with Genentech aims to better understand the genetics of ocular diseases
Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China
A phase I clinical trial for malignant ascites is planned to initiate in China this year.